Therapeutics for neurodegenerative disorders
Sign up today and learn more about Alector Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Alector Stock
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
Founder, President & Chief Executive Officer
Founder & Chairman of the Board
Founder & SAB Member